Iodine-131 (131I) is one of the most frequently used radionuclides for diagnosis and therapy of thyroid diseases. It is administered orally in the treatment of cancer to eliminate the residual postoperative microscopic tumor foci, and the residual normal thyroid tissue for early detection of recurrence [1].
The comparative behavior of 131I concentration into two animalmodels with total and partial thyroid has been investigated in our previous work [2]. The accumulated activities have been measured in fourteen organs.
In this study, the mean absorbed doses resulting from 131I accumulated in all organs have been evaluated using RODES software [3, 4]. With this software, mean absorbed doses were calculatedfor selected organs (thyroid, lungs, heart, liver, kidneys, stomach, spleen, large and small intestine, testes, urinary bladder wall) by combining the specific absorbed fractions (SAF) of energy with radiation emission spectra and biokinetic data determined from our previous experimental study [2]. Calculations were based on the 131I photon and electron emissions reported by [5] and SAFs previously calculated by Monte Carlo simulation in the voxel phantom of an adult male rate [3, 4].
The obtained results show high absorbed dosesdeliveredto stomach and lungs for both models compared to other organs. The dose received by the testes and salivary glands is found to be higher in the case of the rat model without thyroid. Conversely, the spleen and bladder wall received lower doses in this latter model compared to those received by the rat model with thyroid. One can also note that the difference in mean absorbed dose received by liver, lungs, heart, and walls of the stomach is not significant between the two rat models.
Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models
